2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboembolism of Vein VTE in Colorectal Cancer
1
Thromboembolism
1
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Kidney Neoplasms
1
Fatigue
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Gemcitabine
683
130-nm albumin-bound paclitaxel
198
Fluorouracil
188
Oxaliplatin
175
Albumin-Bound Paclitaxel
154
Capecitabine
137
Leucovorin
131
Irinotecan
112
Radiotherapy
96
Taxes
85
pembrolizumab
81
Cisplatin
72
Erlotinib Hydrochloride
70
Radiosurgery
69
Nivolumab
56
Drug Therapy
56
Bevacizumab
54
Magnetic Resonance Spectroscopy
50
Cyclophosphamide
49
folfirinox
45
Specimen Handling
42
Docetaxel
42
Cetuximab
40
irinotecan sucrosofate
38
Biopsy
38
S 1 (combination)
36
Pancreaticoduodenectomy
35
Blood Specimen Collection
34
Surgical Procedures, Operative
31
Paclitaxel
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
isoquercitrin
×
Clear all
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled